Fig. 2.
Median levels of (A) total testosterone, (B) free testosterone, and (C) prostate-specific antigen (PSA) after 2, 4, 6, 8, 12, 18, and 24 wk of treatment with 40 mg estetrol (E4) or placebo in patients with prostate cancer treated with an LHRH agonist (per-protocol population). LHRH = luteinizing hormone-releasing hormone; T = testosterone.